{"id":"NCT01786902","sponsor":"Dong-A ST Co., Ltd.","briefTitle":"Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature","officialTitle":"Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2013-02-08","resultsPosted":"2015-05-29","lastUpdate":"2017-10-19"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Short Stature"],"interventions":[{"type":"DRUG","name":"DA-3002","otherNames":["Recombinant Human Growth Hormone"]}],"arms":[{"label":"DA-3002 Treatment group","type":"EXPERIMENTAL"},{"label":"Non-treatment control group","type":"NO_INTERVENTION"}],"summary":"Growth hormone therapy will improve the height of idiopathic short statured children. DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to non-treatment group in efficacy and safety.","primaryOutcome":{"measure":"Annualized Height Velocity(cm/Year) After 26 Weeks","timeFrame":"26 weeks","effectByArm":[{"arm":"DA-3002 Treatment Group","deltaMin":10.68,"sd":1.95},{"arm":"Non-treatment Control Group","deltaMin":5.72,"sd":1.72}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":36},"commonTop":["Upper respiratory tract infection","Pyrexia","Hypersensitivity","Enteritis","Nausea"]}}